Continuous Subcutaneous Insulin Infusion Market by Product, Patient Type (Type 1 Diabetes, Type 2 Diabetes), End-user

Description

List of Tables

The Continuous Subcutaneous Insulin Infusion Market was valued at USD 2.72 billion in 2023, expected to reach USD 3.05 billion in 2024, and is projected to grow at a CAGR of 12.16%, to USD 6.08 billion by 2030.

Continuous Subcutaneous Insulin Infusion (CSII) involves using insulin pumps to deliver precise doses of insulin necessary for managing diabetes, primarily Type 1. It enhances glycemic control, offering a viable alternative to multiple daily injections. The necessity of CSII arises from its ability to better mimic pancreatic functioning, fostering improved compliance and quality of life among patients. The application extends beyond Type 1 diabetes to some Type 2 patients, gestational diabetes during pregnancy, and challenging pediatric populations. It caters to diverse end-users from hospitals and clinics to home care settings. Market growth is driven by technological advancements, an increasing diabetic population, growing awareness of advanced diabetic solutions, and supportive reimbursement policies. The latest potential opportunities lie in integrating AI and IoT with insulin pumps, facilitating real-time glucose monitoring and predictive analytics. Companies can grasp these opportunities by investing in R&D for smart pumps and by forming strategic partnerships with digital health platforms. However, high device costs, maintenance expenses, and potential technical malfunctions pose challenges. A lack of skilled professionals for device management further hinders widespread adoption. There are also regulatory bottlenecks concerning safety standards and approval timelines. Best opportunities for innovation include developing cost-effective, user-friendly pumps, enhancing cybersecurity measures for digital health devices, and advancing closed-loop insulin delivery systems. Encouraging participatory design approaches within patient communities can provide actionable insights into unmet needs, paving the way for tailored innovations. The CSII market is dynamic, with a competitive landscape spearheaded by a few dominant players, necessitating brands to focus on robust product differentiation and strategic alliances. As personalization in healthcare rises, the market will likely emphasize customized insulin delivery solutions that align with individual patient lifestyles and needs.

KEY MARKET STATISTICS
Base Year [2023]	USD 2.72 billion
Estimated Year [2024]	USD 3.05 billion
Forecast Year [2030]	USD 6.08 billion
CAGR (%)	12.16%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Continuous Subcutaneous Insulin Infusion Market

The Continuous Subcutaneous Insulin Infusion Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Market Drivers
- Rising number of diabetes patients across the world
- Growing awareness of advanced insulin delivery devices
- Rising healthcare expenditure pertinent to diabetes globally
Market Restraints
- High cost of devices
Market Opportunities
- Emerging technological advancements such as AI and IoT
- Ongoing rise in the number of product launches by market players
Market Challenges
- Possible risks such as diabetic ketoacidosis and hypoglycemia

Porter's Five Forces: A Strategic Tool for Navigating the Continuous Subcutaneous Insulin Infusion Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Continuous Subcutaneous Insulin Infusion Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Continuous Subcutaneous Insulin Infusion Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Continuous Subcutaneous Insulin Infusion Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Continuous Subcutaneous Insulin Infusion Market

A detailed market share analysis in the Continuous Subcutaneous Insulin Infusion Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Continuous Subcutaneous Insulin Infusion Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Continuous Subcutaneous Insulin Infusion Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Continuous Subcutaneous Insulin Infusion Market

A strategic analysis of the Continuous Subcutaneous Insulin Infusion Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Continuous Subcutaneous Insulin Infusion Market, highlighting leading vendors and their innovative profiles. These include B. Braun Melsungen AG, Becton, Dickinson and Company, Bigfoot Biomedical, Inc., CeQur Corporation, Fresenius SE & Co. KGaA, MannKind Corporation, Medtronic PLC, MicroPort Scientific Corporation, Nipro Corporation, Sanofi S.A., Shinmyung Mediyes CO., LTD., Smiths Group PLC, SOOIL Developments Co., Ltd., Tandem Diabetes Care, Inc., and Ypsomed AG.

Market Segmentation & Coverage

This research report categorizes the Continuous Subcutaneous Insulin Infusion Market to forecast the revenues and analyze trends in each of the following sub-markets:

Based on Product, market is studied across Patch Pumps and Tethered Pumps. The Patch Pumps is further studied across Basal, Basal & Bolus, and Bous. The Tethered Pumps is further studied across Battery, Insulin Reservoir & Cartridges, and Insulin Set Insertion Devices.
Based on Patient Type, market is studied across Type 1 Diabetes and Type 2 Diabetes.
Based on End-user, market is studied across Homecare, Hospitals, and Laboratory.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-A339DAEFA756

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising number of diabetes patients across the world
  - 5.1.1.2. Growing awareness of advanced insulin delivery devices
  - 5.1.1.3. Rising healthcare expenditure pertinent to diabetes globally
- 5.1.2. Restraints
  - 5.1.2.1. High cost of devices
- 5.1.3. Opportunities
  - 5.1.3.1. Emerging technological advancements such as AI and IoT
  - 5.1.3.2. Ongoing rise in the number of product launches by market players
- 5.1.4. Challenges
  - 5.1.4.1. Possible risks such as diabetic ketoacidosis and hypoglycemia
5.2. Market Segmentation Analysis
5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental

6. Continuous Subcutaneous Insulin Infusion Market, by Product

6.1. Introduction
6.2. Patch Pumps
- 6.2.1. Basal
- 6.2.2. Basal & Bolus
- 6.2.3. Bous
6.3. Tethered Pumps
- 6.3.1. Battery
- 6.3.2. Insulin Reservoir & Cartridges
- 6.3.3. Insulin Set Insertion Devices

7. Continuous Subcutaneous Insulin Infusion Market, by Patient Type

7.1. Introduction
7.2. Type 1 Diabetes
7.3. Type 2 Diabetes

8. Continuous Subcutaneous Insulin Infusion Market, by End-user

8.1. Introduction
8.2. Homecare
8.3. Hospitals
8.4. Laboratory

9. Americas Continuous Subcutaneous Insulin Infusion Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Continuous Subcutaneous Insulin Infusion Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Continuous Subcutaneous Insulin Infusion Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.4. Strategy Analysis & Recommendation

Companies Mentioned

1. B. Braun Melsungen AG
2. Becton, Dickinson and Company
3. Bigfoot Biomedical, Inc.
4. CeQur Corporation
5. Fresenius SE & Co. KGaA
6. MannKind Corporation
7. Medtronic PLC
8. MicroPort Scientific Corporation
9. Nipro Corporation
10. Sanofi S.A.
11. Shinmyung Mediyes CO., LTD.
12. Smiths Group PLC
13. SOOIL Developments Co., Ltd.
14. Tandem Diabetes Care, Inc.
15. Ypsomed AG